Cargando…

A heterologous prime-boosting strategy with replicating Vaccinia virus vectors and plant-produced HIV-1 Gag/dgp41 virus-like particles

Showing modest efficacy, the RV144 HIV-1 vaccine clinical trial utilized a non-replicating canarypox viral vector and a soluble gp120 protein boost. Here we built upon the RV144 strategy by developing a novel combination of a replicating, but highly-attenuated Vaccinia virus vector, NYVAC-KC, and pl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Meador, Lydia R., Kessans, Sarah A., Kilbourne, Jacquelyn, Kibler, Karen V., Pantaleo, Giuseppe, Roderiguez, Mariano Esteban, Blattman, Joseph N., Jacobs, Bertram L., Mor, Tsafrir S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5529300/ https://www.ncbi.nlm.nih.gov/pubmed/28458036 http://dx.doi.org/10.1016/j.virol.2017.04.008

Ejemplares similares

Immunological Characterization of Plant-Based HIV-1 Gag/Dgp41 Virus-Like Particles
por: Kessans, Sarah A., et al.
Publicado: (2016)

Biological and biochemical characterization of HIV-1 Gag/dgp41 virus-like particles expressed in Nicotiana benthamiana
por: Kessans, Sarah A, et al.
Publicado: (2013)

P02-10. Plant expression of chimeric Gag/gp41 virus-like particles as a mucosally-targeted subunit vaccine against HIV-1
por: Kessans, SA, et al.
Publicado: (2009)

Codelivery of improved immune complex and virus-like particle vaccines containing Zika virus envelope domain III synergistically enhances immunogenicity
por: Diamos, Andrew G., et al.
Publicado: (2020)

Preferential targeting of conserved Gag regions after vaccination with a heterologous DNA prime Modified Vaccinia Ankara boost HIV vaccine regime
por: Bauer, A, et al.
Publicado: (2012)

Comparison of Heterologous Prime-Boost Strategies against Human Immunodeficiency Virus Type 1 Gag Using Negative Stranded RNA Viruses
por: Lawrence, Tessa M., et al.
Publicado: (2013)

Immunization of Pigs by DNA Prime and Recombinant Vaccinia Virus Boost To Identify and Rank African Swine Fever Virus Immunogenic and Protective Proteins
por: Jancovich, James K., et al.
Publicado: (2018)

Monkeypox virus induces the synthesis of less dsRNA than vaccinia virus, and is more resistant to the anti-poxvirus drug, IBT, than vaccinia virus
por: Arndt, William D., et al.
Publicado: (2016)

Superluminality in DGP
por: Hinterbichler, Kurt, et al.
Publicado: (2009)

Evaluation of heterologous prime-boost vaccination strategies using chimpanzee adenovirus and modified vaccinia virus for TB subunit vaccination in rhesus macaques
por: Vierboom, Michel P. M., et al.
Publicado: (2020)

Structure and Function of A41, a Vaccinia Virus Chemokine Binding Protein
por: Bahar, Mohammad W, et al.
Publicado: (2008)

Reversal of Succinylcholine Induced Apnea with an Organophosphate Scavenging Recombinant Butyrylcholinesterase
por: Geyer, Brian C., et al.
Publicado: (2013)

Testing the DGP model with ESSENCE
por: Rydbeck, Sara, et al.
Publicado: (2007)

Small Hero with Great Powers: Vaccinia Virus E3 Protein and Evasion of the Type I IFN Response
por: Szczerba, Mateusz, et al.
Publicado: (2022)

Mucosal Vaccines from Plant Biotechnology
por: Mason, Hugh S., et al.
Publicado: (2015)

Heterologous prime-boost vaccination with DNA and MVA vaccines, expressing HIV-1 subtype C mosaic Gag virus-like particles, is highly immunogenic in mice
por: Chapman, Ros, et al.
Publicado: (2017)

Thy1(+) Nk Cells from Vaccinia Virus-Primed Mice Confer Protection against Vaccinia Virus Challenge in the Absence of Adaptive Lymphocytes
por: Gillard, Geoffrey O., et al.
Publicado: (2011)

Classical and Quantum Consistency of the DGP Model
por: Nicolis, A, et al.
Publicado: (2004)

Strong Interactions and Stability in the DGP Model
por: Luty, M A, et al.
Publicado: (2003)

Correction: Thy1(+) Nk Cells from Vaccinia Virus-Primed Mice Confer Protection against Vaccinia Virus Challenge in the Absence of Adaptive Lymphocytes
por: Gillard, Geoffrey O., et al.
Publicado: (2011)

Mucosal Immunization with Newcastle Disease Virus Vector Coexpressing HIV-1 Env and Gag Proteins Elicits Potent Serum, Mucosal, and Cellular Immune Responses That Protect against Vaccinia Virus Env and Gag Challenges
por: Khattar, Sunil K., et al.
Publicado: (2015)

Surprisingly Effective Priming of CD8(+) T Cells by Heat-Inactivated Vaccinia Virus Virions
por: Croft, Sarah, et al.
Publicado: (2020)

Use of a Recombinant Vaccinia Virus Expressing Interferon Gamma for Post-Exposure Protection against Vaccinia and Ectromelia Viruses
por: Holechek, Susan A., et al.
Publicado: (2013)

Attenuation of Vaccinia Virus
por: Yakubitskiy, S. N., et al.
Publicado: (2015)

Vaccinia and Pox-Virus
por: Chalikonda, Sricharan, et al.
Publicado: (2007)

Heterologous prime-boost: an important candidate immunization strategy against Tembusu virus
por: Pan, Yuting, et al.
Publicado: (2020)

P17-23. Enhanced expression of HIV antigens and improved antigen presentation after infection with replication competent attenuated vaccinia virus in vitro
por: Quakkelaar, E, et al.
Publicado: (2009)

Novel Nonreplicating Vaccinia Virus Vector Enhances Expression of Heterologous Genes and Suppresses Synthesis of Endogenous Viral Proteins
por: Wyatt, Linda S., et al.
Publicado: (2017)

Methodology for the Efficient Generation of Fluorescently Tagged Vaccinia Virus Proteins
por: Marzook, N. Bishara, et al.
Publicado: (2014)

Bericht der AG Molekularpathologie-Jahrestagung DGP 2020
por: Haller, F., et al.
Publicado: (2020)

Promotions-, Poster- und Forschungspreis der DGP 2021
Publicado: (2021)

THE CULTIVATION OF THE GRANULES OF VACCINIA VIRUS
por: Craciun, E. C., et al.
Publicado: (1926)

MORPHOLOGICAL STRUCTURE OF THE VIRUS OF VACCINIA
por: Green, R. H., et al.
Publicado: (1942)

CENTRIFUGE EXPERIMENTS WITH THE VIRUS OF VACCINIA
por: Tang, F. F.
Publicado: (1930)

Brazilian Vaccinia Viruses and Their Origins
por: Trindade, Giliane S., et al.
Publicado: (2007)

Lack of Transmission of Vaccinia Virus
por: Stark, James H., et al.
Publicado: (2006)

Enhancing the Immunogenicity of Vaccinia Virus
por: Shchelkunov, Sergei N., et al.
Publicado: (2022)

OA04-02. Strong HIV-specific CD4 and CD8 T-lymphocyte proliferation in HIV-1 DNA prime/modified vaccinia virus Ankara (MVA) heterologous boost vaccinees
por: Nilsson, C, et al.
Publicado: (2009)

Breadth, phenotype and functionality of Gag-specific T cell responses induced by a heterologous DNA/MVA prime-boost HIV-1 vaccine regimen
por: Podola, L, et al.
Publicado: (2012)

Diagnostic accuracy of anti-DGP (IgG) for celiac disease
por: Jafari, Seyed A., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_19uj4o6btp188baq1ratnui3ie